List
The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.
-
Dermal Medical Countermeasures for Chemical Weapons Exposure
SBC: Nano Terra, Inc. Topic: CBD161003Chemical warfare agents (CWAs), such as nerve agents and mustard agents, pose serious threats to our warfighters and civilians. Current formulations of dermal medical countermeasures to CWAs can be absorbed through the skin causing systemic toxicities to the patients. These formulations are limited by the FDA for use only in small area of intact skin, which severely restricts the usefulness of the ...
SBIR Phase I 2017 Department of DefenseOffice for Chemical and Biological Defense -
A novel immunotolerizing therapy for autoimmune vitiligo
SBC: RADIKAL THERAPEUTICS, INC. Topic: NIAMSRadikal Therapeutics RTX is developing a pioneering therapy to restore immunotolerance and arrest progressive depigmentation in vitiligo At our partnering institution Loyola University Chicago a variant to inducible Heat Shock Protein was developed with remarkable potential for the prevention and treatment of autoimmune vitiligo Carrying only a single amino acid modification to the protei ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER
SBC: Stemsynergy Therapeutic Topic: 102ABSTRACT Colorectal cancerCRCrepresents the fourth most commonly diagnosed cancer withnew cases each yearUnfortunatelyCRC results in a disproportionate number of deathsprojected indue to advanced stage at diagnosisthe aggressive phenotype of the disease and lack of effective therapeuticsGreater thanof CRC patients possess activating mutations in the WNT signaling pathwayWNT pathway activation is a ...
SBIR Phase II 2017 Department of Health and Human Services -
An Intraoperative Guidance Platform for Radio Frequency Ablation
SBC: NE Scientific, LLC Topic: 102Project SummaryThe objective of this proposed research program is to develop a platform for planning and guidance during Radio Frequency AblationRFARFA is a thermally mediated ablation techniquewhere an applicator carrying one electrode is inserted into tumors percutaneouslyor via laparoscopyor open surgical approachesRadio FrequencyRFenergy is applieddenaturating and coagulating tissues in a volu ...
SBIR Phase II 2017 Department of Health and Human Services -
Development of PAR2 Pepducins as a Novel NASH Treatment
SBC: OASIS PHARMACEUTICALS, LLC Topic: 300Non alcoholic steatohepatitisNASHis characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosiscirrhosis and high mortality ratesNASH is frequently associated with other common metabolic abnormalitiessuch as insulin resistance and visceral obesityLiver transplantation is currently the only effective therapeutic approach for seve ...
SBIR Phase II 2017 Department of Health and Human Services -
Fracture Risk Assessment Software for Skeletal Metastasis
SBC: BioSensics LLC Topic: NIAMSPROJECT SUMMARY ABSTRACT The skeleton is the third most common site of metastatic cancerand nearly half of all cancers metastasize to boneAs a result of new and aggressive treatments cancer patients are living longerbut at sites of skeletal metastasis fractures occur inof affected bones after minimal traumaThis significantly impacts patient functioning and quality of lifeWhile much has been learne ...
SBIR Phase II 2017 Department of Health and Human Services -
Commercializing Praedicare Dx TM platform for guiding cancer treatments
SBC: Eutropics Pharmaceuticals, Inc. Topic: 102Abstract The Eutropics PraediCare Dxis an emerging clinical diagnostic assay that will be used to predict patient response to specific chemotherapiesUnlike existing assaysPraediCare Dxpredicts response to specific chemotherapies by direct evaluation of cancer cells potential to enter into an apoptotic state following exposure to therapyPraediCare Dxhas the potential to provide actionable data for ...
SBIR Phase II 2017 Department of Health and Human Services -
Novel IL-15 Superagonist Therapy for Bladder Cancer
SBC: Altor Bioscience LLC Topic: NCIProject SummaryBladder cancer is the fifth most common cancer in the U SUp toof patients initially present with non muscle invasive bladder cancerNMIBCconfined to the mucosa of the bladderThese patients are treated by tumor resection followed by intravesical chemotherapy or Bacillus Calmette Gu rinBCGtherapyDespite treatmentup toof patients will experience tumor recurrence andof theseaboutwill und ...
SBIR Phase II 2017 Department of Health and Human Services -
Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapy
SBC: MICROBIOTIX, INC. Topic: NIAAbstractApproximatelymillion Americans have rheumatoid arthritisRAwhich is one of the most common chronic autoimmune disorders in the older populationThere is no cure for RAand up toof patients do not respond to current therapiesAs a resultdisease progression leads to joint destruction and severe disability in the elderlyThereforethe identification of a novel therapeutic strategy used alone or in ...
SBIR Phase I 2017 Department of Health and Human Services -
High channel count electrophysiology and data processing for freely moving animals
SBC: Leaflabs, LLC Topic: 101PROJECT SUMMARY Simultaneous recording and stimulation of larger populations of neurons distributed throughout the brain is needed to rigorously evaluate theories of neural computation at the cellular level in mammals Previously we introduced close packed silicon probes Scholvin et al and a direct to disk data acquisition architecture Kinney et al to enable channel neural ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health